Unruch Joel

Accenture General Counsel Unruch Joel sold 3,563 shares for $1,003,969.80 across 7 transactions on 2025-04-11

General Counsel Joel Unruch executed 7 separate sales totaling 3,563 shares for $1,003,969.80 on April 11, 2025, reducing his holdings from 20,800 shares to 17,237 shares (a -17.1% reduction). The sales span a price range of $278.53 to $284.92 with a blended average of $281.78, occurring at a time when the stock is down -27.2% from its 52-week high and down -9.1% over the past 30 days. Unruch's cross-ticker track record shows a 47.06% well-timed rate on prior sells with average 90-day returns of +1.0%, but his same-ticker history at ACN is mixed: recent January 2025 sales show positive 30-day returns of +0.8%, +0.3%, and +0.5%, while his October 2024 sales were poorly timed with negative 90-day returns of -3.4% and -4.1%. This sale occurs amid a 90-day stock decline of -17.0%, which would suggest favorable timing if the downward trend continues, though his predictive accuracy specifically at ACN remains inconsistent.

Accenture General Counsel sells 4,750 shares for $1,723,184.89; cross-ticker history shows 45.00% well-timed rate; ACN same-ticker prior sales 80% well-timed at 90-day mark

General Counsel Joel Unruch executed 3 separate sales totaling 4,750 shares for $1,723,184.89 at prices ranging from $361.25 to $363.16, reducing his holdings by 18.8% from the pre-transaction level of 25,276 shares. His cross-ticker track record across 20 prior open-market sales shows a 45.00% well-timed rate (90-day negative returns), though average 90-day returns of +2.7% suggest overall modest timing performance; notably, his same-ticker history at ACN shows 4 of 5 prior sales were well-timed at the 90-day mark, establishing a pattern of selling before subsequent price weakness at this issuer. The current price of $373.15 is 3.6% below the 52-week high of $386.91, and the stock has gained 4.8% over the prior 30 days, creating a context where this sale occurs near recent strength but with limited downside cushion from year-to-date peaks.

ACN General Counsel Unruch Joel sold 4,750 shares for $1,757,378.04 on 2024-10-23 at blended average $369.97.

Joel Unruch, General Counsel and Corporate Secretary, executed four separate sales on October 23, 2024, totaling 4,750 shares for $1,757,378.04, representing a 17.1% reduction in his post-transaction holdings to 22,976 shares. The transaction prices ($369.05–$371.65) sit above the current price of $364.23, though near the 52-week high of $386.91. Among his five prior same-ticker sales at ACN, the 90-day timing pattern shows 0 of 5 were well-timed (stock rose after in most cases), contrasting with his broader cross-ticker track record of a 42.11% well-timed rate across 19 prior sells. The stock has delivered +10.9% over 90 days and +7.2% over 30 days, reflecting strong recent momentum despite the elevated P/E of 31.59. This sale reduces a meaningful executive position and occurs during a period of stock strength, warranting observation of whether this signals a shift in insider appetite or reflects personal portfolio management absent any disclosed material concerns.

ACN General Counsel/Corp Secretary sold 8,145 shares for $2,696,423.15 on 2024-07-22, reducing holdings 26.3%.

Joel Unruch executed 3 separate sales totaling 8,145 shares for $2,696,423.15 at blended average price $331.05 on 2024-07-22, reducing his post-transaction holdings to 22,849 shares from 30,994 shares (a 26.3% reduction). At ACN, his 5 prior open-market sales showed mixed timing: 1 of 5 were well-timed at the 90-day mark, with the most recent cluster (three sales on 2024-04-19) each posting negative 30-day returns (-3.7% to -4.5%) followed by positive 90-day returns (+3.2% to +4.1%), indicating he sold before near-term weakness but the declines reversed. The current transaction occurred at $331.05, near the current price of $330.33, against a 52-week high of $386.91 (stock is -14.6% from that peak). Given his modest cross-ticker track record (90-day well-timed rate of 50.00%) and the limited predictive signal from same-ticker history at ACN, this sale warrants monitoring but does not indicate a material shift in confidence.